Biotechnology

Hemogenyx Pharmaceuticals PLC Announces Hemo-CAR-T partnership with WuXi ATU

December 20, 2021 2:00 AM

Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme LONDON, UK / ACCESSWIRE / December 20, 2021 / Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies' ("WuXi ATU") plasmid and lentiviral vector manufacturing platforms, including integrated testing, to accelerate HEMO-CAR-T programme for acute myeloid leukaemia ("AML") toward phase I clinical trials....

Read more

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

December 17, 2021 1:15 PM

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) Partial response in metastatic uveal melanoma, a difficult-to-treat indication Markedly improvement of stage IV sarcoma BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the...

Read more

Oncology Pharma Meeting Towards Future Developments

December 17, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scientific Advisory Board members along with legal counsel, which shared updates on progress made towards the development of the Company's licensed products. This marked progress towards pursuing its primary goal of the Co-Development plan to bring new...

Read more

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

December 16, 2021 2:45 PM

KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the "Contract") for media buys and digital marketing with SRAX, Inc. ("SRAX"). "Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long...

Read more

M2Bio Director of Health and Fitness Rob Simbowe Visits Zambia and Hosts Vulnerable Youth Symposium

December 16, 2021 10:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 16, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: M2Bio Sciences is pleased to announce its Director of Health and Fitness, Brand Ambassador, and MMA Champion Rob Simbowe (AKA Black Tiger) visited Zambia and hosted the Vulnerable Youth Program...

Read more

Vero Diagnostics Lab Launches Ultra-Rapid Covid-19 PCR Testing in Los Angeles

December 16, 2021 10:00 AM

Market's fastest PCR test to provide results to thousands per day, with results in as little as one hour LOS ANGELES, CA / ACCESSWIRE / December 16, 2021 / Vero Diagnostics, a CLIA high complexity & CAP certified, state-of-the-art laboratory, today announced the launch of the Baebies® FINDER® 1.5 ultra-rapid SARS-CoV-2 RT-PCR testing platform to Vero Diagnostics customers in Los Angeles. Ultra-rapid RT-PCR testing instruments installed at the...

Read more

Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

December 15, 2021 5:30 PM

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021. OVERVIEW The Company reported a net loss and total comprehensive loss for the...

Read more

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

December 15, 2021 8:05 AM

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing...

Read more

Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

December 14, 2021 11:50 AM

KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. Formal hospital and ethics board approvals for human clinical study HYPER-H21-3 had been received in March. Study HYPER-H21-3 used a placebo-controlled...

Read more

CB Scientific, Inc. Enters Beta-testing Phase for Its Updated Proprietary My-Cam Cardiac Event Monitor

December 14, 2021 6:00 AM

Updates to provide device improvements while maintaining the innovative core-functionality of CBSC's state-of-the-art cardiac event monitor ESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company has entered the Beta testing phase for its updated My-Cam cardiac event monitoring device. The updated design provides improved power consumption, enhanced lead wire...

Read more

Helix BioPharma Corp. Extends Period to Exercise Warrants

December 13, 2021 6:25 PM

RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it is extending the exercise period of a total of 1,520,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties, for a period of two years...

Read more

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting Request

December 13, 2021 4:20 AM

LONDON, UK / ACCESSWIRE / December 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce significant progress in relation to moving its lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") toward clinical trials. The Company has applied for a pre-Investigational New Drug ("PIND") application meeting with the...

Read more

BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

December 11, 2021 5:45 PM

Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma Complete responses lasting beyond 18, 24 and 36 months LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim...

Read more

BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

December 10, 2021 7:15 AM

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application...

Read more

Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results

December 9, 2021 5:45 PM

RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2021 fiscal year ended July 31, 2021. OVERVIEW The Company reported a net loss and total comprehensive loss of $8,038,000 or $0.06...

Read more

Applied UV Announces the Appointment of James Alecxih as Chief Executive Officer

December 9, 2021 8:00 AM

Highly Accomplished Executive with Proven Track Record of Leading Healthcare Businesses Q Saeed to transition to consultant to the Company MOUNT VERNON, NY / ACCESSWIRE / December 9, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an industry leader in air and surface pathogen elimination technology today announced that its Board of Directors has appointed James Alecxih as Chief Executive Officer and as a member of the...

Read more

Oncology Pharma Year End Review and Outlook

December 9, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provide an outlook for what to look for in the coming months and year ahead. The Company is proud of the progress it has made this past year including the addition of a renowned Chairman to the Scientific Advisory Board, retaining a PCAOB audit firm,...

Read more

Wuhan Acquires Remaining Shares in Tsime

December 8, 2021 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 8, 2021 / WUHAN GENERAL GROUP (CHINA), INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: Following the acquisition of 60% of Tsime Pharmaceuticals and Medical Supplies (Pty) Ltd ("Tsime") in 2020, WGG has now reached an agreement with the remaining shareholders...

Read more

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

December 8, 2021 7:30 AM

Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its...

Read more

BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors

December 8, 2021 2:20 AM

LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV) BioInvent's pipeline expanding to four drug candidates in five clinical trials Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial...

Read more